Condition: Rectal Adenocarcinoma · High-Risk Cancer · MSS · Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
To explore the efficacy and safety of short-course radiotherapy combined with mFOLFOX6, PD-1 monoclonal antibody and cetuximab (for RAS/BRAF Wild-Type)/bevacizumab (for RAS/BRAF Mutant) in High-Risk pMMR/MSS Rectal Adenocarcinoma through a prospective study, providing high-level evidence-based medical evidence for the use in the treatment of high-risk rectal cancer.
This description comes directly from the study's public registry record.
Jun Huang, PhD. · +8613926451242 · huangj97@mail.sysu.edu.cn
Fang He, MD. · +8618826059789 · hefang23@mail.sysu.edu.cn
Always discuss trial participation with your own doctor first.
| Sixth Affiliated Hospital, Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06908031